In this Issue:
Survival rates after bilateral mastectomy vs alternatives
PALB2 gene mutation increases BC risk
Safety profile of T-DM1 in metastatic BC
MammaPrint testing impacts on chemotherapy decisions
Long-term follow-up data for postmastectomy RT
Benefits with adjuvant use of zoledronic acid
Validity of neoadjuvant anti-HER2 therapy
Tumour T cell infiltration may improve risk stratification
Tumour infiltrating lymphocytes prognostic in TNBC
Taxane-based therapy in intermediate-risk early BC
Neoadjuvant therapy in operable TNBC
Please login below to download this issue (PDF)